Intermittent Fasting in Cancer: a Role in Survivorship?
- 31-05-2022
- Cancer (RA Murphy, Section Editor)
- Authors
- Eleah Stringer
- Julian J. Lum
- Nicol Macpherson
- Published in
- Current Nutrition Reports | Issue 3/2022
Abstract
Purpose of Review
To discuss the historical development of intermittent fasting, its potential underlying mechanisms, and the state of clinical trials, and to reflect on considerations for practice and future recommendations.
Recent Findings
Preclinical studies consistently show the robust disease-modifying efficacy of intermittent fasting in various metabolic diseases which may hold implications for cancer prevention and survivorship. Twenty-one clinical trials have or are being conducted on fasting in cancer, utilizing various fasting regimens across different tumor types as a stand-alone intervention or in adjunct to anticancer treatment, with heterogenous outcome variables.
Summary
Though there are no known, reproducible diets, to cure or prevent cancer recurrence, preliminary research on the underlying mechanisms, tolerance, and safety of intermittent fasting in cancer warrants further investigation. The inherent flexibility of intermittent fasting to accommodate all types of diets is of necessity in oncology.
Advertisement
- Title
- Intermittent Fasting in Cancer: a Role in Survivorship?
- Authors
-
Eleah Stringer
Julian J. Lum
Nicol Macpherson
- Publication date
- 31-05-2022
- Publisher
- Springer US
- Published in
-
Current Nutrition Reports / Issue 3/2022
Electronic ISSN: 2161-3311 - DOI
- https://doi.org/10.1007/s13668-022-00425-0
This content is only visible if you are logged in and have the appropriate permissions.
This content is only visible if you are logged in and have the appropriate permissions.